Open Orphan #ORPH – DNDi Phase II trial to support river blindness drug July 29, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan plc (AIM: ORPH), a rapidly growing specialist clinical research organisation (CRO) which is the world leader in testing vaccines and antivirals using human challenge clinical trials, announces a contract to supply consultancy services to support a Phase II trial in Onchocerciasis Disease, an infectious disease commonly known as river blindness. Venn Life Sciences (“Venn”), a subsidiary of Open Orphan, will provide Data Management & Biostatistics services to support the Phase II trial of…

Continue reading